PRXS571 is a potent modulator of the neuronal integrated stress response (ISR) and can be used in neural-related research[1].

PRY Human Pre-designed siRNA Set A contains three designed siRNAs for PRY gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PRY2 Human Pre-designed siRNA Set A contains three designed siRNAs for PRY2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSAP Human Pre-designed siRNA Set A contains three designed siRNAs for PSAP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSAR18-COOH is a derivative of PSAR extracted from patent WO2009064913A1. PSAR is a highly hydrophilic, biodegradable, non-immunogenic and water-soluble polymer that has been employed in several delivery systems for drugs or diagnostics.

PSAR18-COOH is a derivative of PSAR extracted from patent WO2009064913A1. PSAR is a highly hydrophilic, biodegradable, non-immunogenic and water-soluble polymer that has been employed in several delivery systems for drugs or diagnostics.

PSAR18-COOH is a derivative of PSAR extracted from patent WO2009064913A1. PSAR is a highly hydrophilic, biodegradable, non-immunogenic and water-soluble polymer that has been employed in several delivery systems for drugs or diagnostics.

PSAR18-COOH is a derivative of PSAR extracted from patent WO2009064913A1. PSAR is a highly hydrophilic, biodegradable, non-immunogenic and water-soluble polymer that has been employed in several delivery systems for drugs or diagnostics.

PSAT1 Human Pre-designed siRNA Set A contains three designed siRNAs for PSAT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSB-1434 is an inhibitor for monoamine oxidase B (MAO-B), with an IC50 of 1.59 nM[1].

PSB-1491 is a selective and competitive monoamine oxidase B (MAO-B) inhibitor with an IC50 of 0.386 nM for hMAO-B. PSB-1491 shows >25000-fold selective versus MAO-A[1].

PSB-SB1202 (Compound 21a) is a phenyl coumarin compound. PSB-SB1202 is a CB1/CB2 agonist with EC50 values of 56 and 14 nM, and Ki values of 32 and 49 nM, respectively[1].

PSCA Human Pre-designed siRNA Set A contains three designed siRNAs for PSCA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSD Human Pre-designed siRNA Set A contains three designed siRNAs for PSD gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSD2 Human Pre-designed siRNA Set A contains three designed siRNAs for PSD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSD3 Human Pre-designed siRNA Set A contains three designed siRNAs for PSD3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSD4 Human Pre-designed siRNA Set A contains three designed siRNAs for PSD4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSEN1 Human Pre-designed siRNA Set A contains three designed siRNAs for PSEN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSEN2 Human Pre-designed siRNA Set A contains three designed siRNAs for PSEN2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSENEN Human Pre-designed siRNA Set A contains three designed siRNAs for PSENEN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSG1 Human Pre-designed siRNA Set A contains three designed siRNAs for PSG1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSG11 Human Pre-designed siRNA Set A contains three designed siRNAs for PSG11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSG2 Human Pre-designed siRNA Set A contains three designed siRNAs for PSG2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSG3 Human Pre-designed siRNA Set A contains three designed siRNAs for PSG3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSG4 Human Pre-designed siRNA Set A contains three designed siRNAs for PSG4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSG5 Human Pre-designed siRNA Set A contains three designed siRNAs for PSG5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSG6 Human Pre-designed siRNA Set A contains three designed siRNAs for PSG6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSG7 Human Pre-designed siRNA Set A contains three designed siRNAs for PSG7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSG8 Human Pre-designed siRNA Set A contains three designed siRNAs for PSG8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSG9 Human Pre-designed siRNA Set A contains three designed siRNAs for PSG9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSI-6206-d1,13C,15N2 is 15N and 13C labeled PSI-6206 (HY-15236). PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.

PSIP1 Human Pre-designed siRNA Set A contains three designed siRNAs for PSIP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSKH1 Human Pre-designed siRNA Set A contains three designed siRNAs for PSKH1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PSMA binder-1 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging […]

PSMA binder-1 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging […]

PSMA binder-1 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging […]

PSMA binder-1 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging […]

PSMA binder-1 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging […]

PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging […]

PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging […]

PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging […]

PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging […]

PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging […]